INTRODUCTION
Resident microbiota in h�mans colonizes bo�ndary s�rfaces maintaining imm�ne homeostasis [�] . Imba lance in microbial comm�nities� or microbial dysbiosis� has been shown to contrib�te to the cancero�s patho genesis and progression incl�ding breast cancer [�� �]. Microbial glycans are key antigens in hostmicrobial interactions [4] . Blood gro�p related cryptic glycans Thomsen -Friedenreich �TF� Galβ���GalNAcα�� Tn �GalNAcα� and αGal �Galα���Galβ� and/or mimicking determinants are present in enteric bacteria [5��] . Besides� TF and Tn are t�morassociated glycans �TAG� beca�se they are freq�ently expressed in adenocarci nomas. The increased expression of TF and Tn is asso ciated with the t�mor invasion and metastases [����] . The αGal epitope is aberrantly expressed in h�man cells and it may be involved in a�toimm�ne diseases [�] . Be ing a constant so�rce of foreign antigens� microbiota stim�lates the prod�ction of antiglycan antibodies. It is considered that the nat�ral antiTF� Tn and αGal antibodies in h�man are ind�ced by enteric microorga nisms [5� �]. The high IgG antibody level and its change may reflect the adaptive imm�ne response of the host to microorganisms or increased a�toreactivity to self an tigens. Comparative data abo�t spontaneo�sly occ�r ring antiglycan antibodies in cancer� their a�toreactivity to "self" and "altered self" antigens incl�ding TAG de serve a circ�mstantial investigation. We demonstrated the prognostic significance of the level of ser�m IgG antibodies to some glycans� and its relation to clinical parameters� t�mor progression and histopathological grading in gastrointestinal cancer patients [�����] . The antibody response to microbial glycans and its rela tion to s�rvival has not been chara cterized in patients with breast cancer yet.
The aim of the present st�dy was to eval�ate whe ther the level of IgG antibodies to TFpAA� TnPAA and αGalPAA is related to s�rvival of patients with breast cancer� taking also into consideration the stage of the disease� t�mor vol�me� morphology and the t�mor spread in regional lymph nodes.
MATERIALS AND METHODS

Patients.
The investigation was carried o�t in ac cordance with the ICH GCP Standards and approved by Tallinn Medical Research Ethics Committee� Esto nia. The informed consent was obtained from each patient �nder examination. Females with breast cancer in stages I�III �n = 59� whose diagnosis was verified by the pTNM system [�4]� were incl�ded in the st�dy. The chemo and Xray therapyprescribed patients as well as patients who died of ca�ses other than t�mor rec�rrence were excl�ded from the st�dy. The median and mean age ± SD was 5�.5 and 5�.� ± 9.4.
Glycoconjugates. Isoelectric focusing (IEF) and Western blotting. IEF was performed in a �% agarose IEF �GE Healthcare BioSciences AB� Sweden� containing ��% glycerol as described in [��] . A pH gradient was formed in the gel with 4% Ampholytes high resol�tion ���� �Sigma Aldrich� USA� and �% Pharmalyte 5�� �GE Healthcare BioSciences AB� Sweden�.
Statistical analysis. The levels of antibodies were st�died in relation to overall s�rvival time starting from the date of the preoperatively taken blood sample. The Kaplan -Meier method was �sed for the esti mation of s�rvival c�rves in the �nivariate analysis of patients gro�ps� the significance of differences was analyzed by the logrank test. The Cox proportional hazards model was �sed to eval�ate the risk of death. Statistical analysis was performed �sing SPSS� ver sion ��.�. The median �M� of the level of antiTFpAA� Tn and αGal antibodies was �sed as c�toff to dis criminate between responders �R� the level above or eq�al to M� and weak responders �WR� the level below M�. S�rvival of R vs WR was eval�ated in s�b gro�ps divided by stages� t�mor vol�me� t�mor grade and regional lymph node metastases. The difference in s�rvival between patient gro�ps was considered to be significant when p ≤ �.�5.
RESULTS
Median and mean of the preoperative antibody le vels shown in Table � The specificity of antiTFpAA antibodies affinity isolated from cancero�s sera was described ear lier [��] . In the present st�dy� we analyzed antibodies �sing IEF and the IgGWestern blotting and showed their polyclonal pattern �Fig. ��. 
DISCUSSION
We demonstrated earlier an association of the level of examined antibodies with s�rvival of patients with gastrointestinal cancer incl�ding pathomorphological s�bgro�ps. A significantly better s�rvival has been ob served in patients with an increased level of antibodies to TFpAA and TnPAA while� on the contrary� a signifi cantly worse s�rvival was observed in an increased anti αGalPAA IgG level or its postoperative elevation [��] . The present st�dy demonstrates an association of the ser�m level of antiTFpAA IgG and trend to associa tion of antiTn and antiαGal IgG with s�rvival of breast cancer patients. Better s�rvival was revealed in an in creased level of antiTFpAA antibodies for all gro�p. Similar to patients with gastrointestinal cancer� a better s�rvival of TFR was observed in s�bgro�ps of an ad vanced breast cancer and G� t�mor �see The low IgG reactivity to TFpAA in patients with cancer may be d�e to the presence of ser�m factors that infl�ence the detection of antibodies. Nat�ral antiglycan antibodies are mostly IgMclass antibo dies. IgM with corresponding specificities can compete with IgG for binding to glycan in ELISA and thereby red�ce IgG signal [��] . As a r�le� we observed a low IgM reactivity to TFpAA in ser�m samples with a high corresponding IgG reactivity b�t inverse correlation was not revealed. No difference in s�rvival of gastric cancer patients was demonstrated in relation to the antiTF pAA IgM level [��] . The other ser�m factor that can red�ce IgG binding to TFpAA and thereby red�ce the signal of antibodies in ELISA is the TFbinding protein galectin �. Ser�m levels of galectin � in patients with breast and gastrointestinal cancer were significantly elevated especially in metastatic gastrointestinal carci noma as compared with healthy individ�als [��] . A high level of galectin � is associated with the worse s�rvival of colorectal cancer patients [��] . The increased level of galectin � in advanced cancer and its competition may be an additional factor improving eval�ation of s�rvival �sing determination of IgG reactivity �level� to TFpAA. This s�pposition needs f�rther detailed investigations.
Antiglycan antibodies belong to nat�ral antibo dies. Comm�nities of microbiota transmitted from mother to newborn remain stable in lifetime. The nat�ral IgG antibodies are also transferred from mother to fet�s and the repertoire of IgG a�toantibodies remains stable [��� �4���]. We observed a similar pattern of antiTFpAA� Tn and αGal IgG in sera of grand mother� mother and her ad�lt son; moreover� everyone of donors had a high level of antiTFpAA and antiαGal IgGs. In most gastrointestinal cancer patients the an tibodies level is slightly changed b�t in some patients we observed a high level of antiglycan IgG and its postoperative elevation [��� ��� ��]. A very high level of antiTFpAA IgG was marked in eight longterm s�rvivors in stages II�III among ��4 patients �nder st�dy [��] . The twelvefold change of the antiTFpAA IgG level was noted in the follow�p. In one case the stable increase over the backgro�nd level co�ld be d�e to prolonged chemotherapy. The antiTFpAA IgG level correlated with a co�nt of blood lymphocytes and in versely correlated with ne�trophil/lymphocyte ratio [��� ��]. Together these observations point to the adaptive antiTFpAA IgG response at least in some patients.
Antiglycan antibodies associated with s�rvival may be involved in cancer progression thro�gh different path ways. Some of them are crossreactive to histoblood gro�p related antigens that may be aberrantly expressed in t�mors as prec�rsors or incompatible antigens [��] . Some genera of microbiota might express TAGmimic antigens and stim�late TAGa�toreactive antibodies� which may be beneficial or adverse for cancer patients.
To characterize the specificity of antibodies� anti TFpAA IgGs were affinityisolated from the ser�m samples of longterm s�rvivors� �sing different TFα conj�gated sorbents. AntiTFpAA IgG displayed a low specificity to the m�cino�s fraction isolated from malignant breast t�mors except three specimens [��� �9]. Affinityisolated antiTn and αGal IgG also were low specific. The crossreactivity of antiTFpAA IgG to different determinants incl�ding TFα�nrelated reactivity and reactivity to the pAA carrier witho�t glycans was revealed. We renamed term �sed ear lier "antiTF IgG" to "antiTFpAA IgG". Antibodies were more reactive to TFβ �Galβ���GalNAcβ� than to TF �TFα� conj�gates� and they were a heterogenic pop�lation varying in the crossreactivity to glycolipid related glycans with TFβ terminal resid�es� GA� and Gb5 tri [��� ��� ��]� the latter being a terminal trisac charide of Gb5 �stagespecific embryonic antigen �� SSEA��� which is expressed in ��.5% of breast cancer specimens [��] . The specificity to the pAA carrier and ��%TFαpAA b�t not to the standart ��%TFαPAA� which was inherent in all IgG s�bpop�lations incl�ding those isolated witho�t carrier� is enigma [��] . These IgG s�bpop�lations belong to polyclonal antibodies �see Fig. �� . The pAAmimic �glyco�peptide seq�ences of �nknown proteins may be nat�ral determinants for antibodies. The identification of nat�ral targets co�ld el�cidate the direct or indirect relation of a longlasting antiTFpAA IgG imm�ne response to s�rvival.
Dysbiosis is associated with a breast cancer state and severity. The total bacterial DNA load was red�ced in the t�mor as compared to normal tiss�e and corre lated inversely with an advanced disease [�] . Dysbiosis may infl�ence the t�mor development via complex interrelations within the triad: resident microbiotat�mor -imm�ne response in which some antiglycan antibodies might be involved. The dynamic st�dy of the h�moral imm�ne response �sing glycomics together with microbial genomics can el�cidate interrelations leading to the carcinogenesis and t�mor progression.
CONCLUSIONS
The present st�dy demonstrates prognostic sig nificance of antiTFpAA IgG� which is acceptable not only for gastrointestinal cancer b�t also for breast can cer. The noninvasive screening test may be a �sef�l s�pplement in clinical o�tcome assessment.
